Lees Pharmaceutical Hldgs 

$0.190300
2
+$0.00+1.12% Monday 20:00

統計

當日最高
0.2
當日最低
0.2
52週高點
0.2
52週低點
0.1882
成交量
6,000
平均成交量
0
市值
112.06M
本益比
18.82
股息殖利率
3.06%
股息
0.01

即將到來

股息

3.06%股息殖利率
Jun 26
$0.00
Oct 25
$0.00
Jun 25
$0.00
Oct 24
$0.00
Jun 24
$0.00
10年成長
-8.35%
5年成長
-5.99%
3年成長
35.84%
1年成長
-4.21%

財報

2Sep預期
Q4 2017
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
下一步
0.08
0.09
0.1
0.11
預期EPS
不適用
實際EPS
不適用

財務

6.65%利潤率
有盈利
2019
2020
2021
2022
2023
2024
360.03M營收
23.93M淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 LPCUF 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Lee's Pharmaceutical Holdings Limited functions as an investment holding company primarily focused on the development, manufacturing, and commercialization of pharmaceutical products within the People's Republic of China. The company's therapeutic scope is broad, addressing various medical conditions across diverse areas such as cardiovascular health, women's health, pediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. Its business operations are structured into two main segments: Proprietary and Generic Products, and Licensed-In Products. The Proprietary and Generic Products segment is responsible for producing and selling both its own internally developed medications and generic versions of established drugs. Notable products in this category include Livaracine, used to treat blood clots and deep vein thrombosis; Yallaferon for viral infections; Slounase, an agent for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection, also for deep vein thrombosis; and Sodium Phenylbutyrate Granules, which treat urea cycle disorders. Conversely, the Licensed-In Products segment manages the distribution and commercialization of pharmaceutical products obtained through licensing agreements with other companies. This extensive portfolio encompasses treatments such as Carnitene for carnitine deficiency; Aloxi and Sancuso for managing chemotherapy-induced nausea and vomiting; Bredinin, an immunosuppressant used in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil, which alleviates oral mucositis pain; Ferplex for iron deficiency anemia; and Gaslon N for gastric ulcers and gastritis. Additional offerings include Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution for primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan, indicated for Stage III and IV Hodgkin's disease; Omacor, containing Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik for Amyotrophic lateral sclerosis; Trittico for insomnia and depression; Unidrox for urinary and respiratory tract infections; the probiotics Dicoflor and VSL#3; and Zingo, a topical local analgesic. Lee's Pharmaceutical was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
Show more...
執行長
Ms. Siu Fong Lee
員工
1022
國家
開曼群島
ISIN
KYG5438W1116

上市

0 Comments

分享你的想法

FAQ

Lees Pharmaceutical Hldgs 今天的股價是多少?
LPCUF 目前價格為 $0.19 USD,過去 24 小時上漲了 +1.12%。在圖表上更密切關注 Lees Pharmaceutical Hldgs 股價表現。
Lees Pharmaceutical Hldgs 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Lees Pharmaceutical Hldgs 的股票以代號 LPCUF 進行交易。
Lees Pharmaceutical Hldgs 的市值是多少?
今天 Lees Pharmaceutical Hldgs 的市值為 112.06M
Lees Pharmaceutical Hldgs 下一次財報日期是什麼時候?
Lees Pharmaceutical Hldgs 將於 September 02, 2026 公布下一次財報。
Lees Pharmaceutical Hldgs 去年的營收是多少?
Lees Pharmaceutical Hldgs 去年的營收為 360.03MUSD。
Lees Pharmaceutical Hldgs 去年的淨利是多少?
LPCUF 去年的淨收益為 23.93MUSD。
Lees Pharmaceutical Hldgs 會發放股息嗎?
是的,LPCUF 的股息每 半年一次 發放一次。每股最新股息為 0 USD。截至今日,股息殖利率(FWD)% 為 3.06%。
Lees Pharmaceutical Hldgs 有多少名員工?
截至 June 23, 2026,公司共有 1,022 名員工。
Lees Pharmaceutical Hldgs 位於哪個產業?
Lees Pharmaceutical Hldgs從事於Health & Wellness產業。
Lees Pharmaceutical Hldgs 何時完成拆股?
Lees Pharmaceutical Hldgs 最近沒有進行任何拆股。
Lees Pharmaceutical Hldgs 的總部在哪裡?
Lees Pharmaceutical Hldgs 的總部位於 開曼群島 的 Sha Tin。